Compare Strategy Inc. (MSTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Strategy Inc. trades at $154.34 (market cap $60.40B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Strategy Inc. is far larger — about 28.2× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 23,421,830). Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MSTR | RXRX | |
|---|---|---|
Market Cap | $60.40B | $2.14B |
Volume | 23,421,830 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $320.29 | $6.79 |
52-Week Low | $82.31 | $2.84 |
Typical Hold Time | 112 Days | 23 Days |
Enterprise Value | $79.16B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $154.34, up 0.63% with a bullish technical signal and strong analyst support. The company shows concerning fundamentals with negative net income margins of -6,102.96% and three consecutive earnings misses, though revenue remains stable around $477 million. Recent news highlights Citigroup's upgraded price target to $240 and the stock's 35% monthly surge, positioning it as a high-risk, high-reward play tied to Bitcoin market movements despite operational challenges.
Outlook remains polarized: 62% analyst buy ratings and a $253 consensus target suggest 64% upside, but extreme profitability risks and volatile cash flows demand caution. Investment opportunity hinges on Bitcoin's performance amplifying equity value, while risks include persistent losses, debt burden, and sensitivity to crypto market swings.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
